Dollar Holds Steady as Markets Shift Focus to 2026 Rate Cut Expectations 
Magnum Audit Flags Governance Issues at Ben & Jerry’s Foundation Ahead of Spin-Off 
Trump Administration to Secure Equity Stake in Pat Gelsinger’s XLight Startup 
China Urged to Prioritize Economy Over Territorial Ambitions, Says Taiwan’s President Lai 
Japan’s Finance Minister Signals Alignment With BOJ as Rate Hike Speculation Grows 
Asian Markets Mixed as Fed Rate Cut Bets Grow and Japan’s Nikkei Leads Gains 
U.S. Backs Bayer in Supreme Court Battle Over Roundup Cancer Lawsuits 
GM Issues Recall for 2026 Chevrolet Silverado Trucks Over Missing Owner Manuals 
IKEA Launches First New Zealand Store, Marking Expansion Into Its 64th Global Market 
Apple Appoints Amar Subramanya as New Vice President of AI Amid Push to Accelerate Innovation 
Asian Markets Stabilize as Wall Street Rebounds and Rate Concerns Ease 
Dollar Slips as Weak U.S. Manufacturing Data Increases Pressure for Fed Rate Cuts 
Momenta Quietly Moves Toward Hong Kong IPO Amid Rising China-U.S. Tensions 
Amazon Debuts “Amazon Now” for 30-Minute Ultrafast Grocery Delivery 
China’s Services Sector Posts Slowest Growth in Five Months as Demand Softens 
South Korea Inflation Edges Up in November as Food and Service Costs Climb 
ExxonMobil to Shut Older Singapore Steam Cracker Amid Global Petrochemical Downturn 
Bristol Myers Squibb has been sued for $6. 4 billion for allegedly delaying a cancer drug. In the new lawsuit, it was claimed that the American multinational pharmaceutical company headquartered in New York improperly held up the development of a medicine for the treatment of non-Hodgkin's lymphoma.
The allegation against the pharma company
According to Reuters, it was alleged that Bristol Myers Squibb deliberately delayed the development so it can avoid paying $6.4 billion to Celgene Corp. shareholders. Bristol Myers acquired this drug manufacturing company in 2019.
Based on the complaint that was filed at the Manhattan federal court on Thursday, June 3, the company would have owed the said amount if it had received the approval from the U.S. Food and Drug Administration for specified deadlines for three drugs that Celgene had been developing.
In the filing, it was stated that the pharmaceutical company failed to use contractually required "diligent efforts" to get the FDA’s approval for the cancer drug called Breyanzi before the set deadline of Dec. 31, 2020. Now, with no approval before the deadline, the company was excused from paying the sum to Celgene.
It was reported that the lawsuit was filed by the UMB Bank NA, which is acting as a trustee for Celgene’s former shareholders. Bristol-Myers acquired Celgene under a $80.3 billion deal that was signed in November 2019.
Bristol Myers Squibb accused of misconduct
The former shareholders think that Bristol Myers did not exert efforts to beat the deadline when it was supposed to get the FDA’s approval for Breyanzi. They are suspecting that the company did this deliberately to avoid paying them, so they are accusing Bristol Myers of “blatant misconduct,” as per Fierce Pharma.
Finally, the case against Bristol Myers was recorded under 1:21-cv-04897 in the U.S. District Court-Southern New York. The shareholders that were represented by UMB Bank NA sued the pharma firm for breaching the CVR agreement through its failure to exert efforts to secure the needed approval from the FDA.
